VEGFA and ovarian cancer: A successful example of such a synergy is given by the combination of olaparib with the pan-VEGF inhibitor cediranib, which increased median progression-free survival from 9 to 17.7 mo compared with olaparib alone in platinum-sensitive ovarian cancer (Liu et al. 2014).